Literature DB >> 30578037

Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease-A five-year follow-up study.

Hao-Min Cheng1, Ling-Jan Chiou2, Tzu-Ching Chen3, Shih-Hsien Sung4, Chen-Huan Chen5, Hui-Chu Lang6.   

Abstract

OBJECTIVE: To evaluate the cost-effectiveness of using drugeluting stents (DES) compared to bare-metal stents (BMS) for coronary heart disease (CHD). DATA SOURCES/STUDY
SETTING: Data were obtained from the National Health Insurance Longitudinal Health Insurance Database, which contains claims data for 1,000,000 beneficiaries. The data were randomly sampled from all beneficiaries. STUDY
DESIGN: A retrospective claims data analysis. DATA COLLECTION/EXTRACTION
METHODS: Patients with stable coronary heart disease who underwent coronary stent implantation from 2007 to 2008 were recruited and followed to the end of 2013. After a 2:1 propensity score matched by gender, age, stent number, and the Charlson comorbidity index (CCI), 852 patients with 568 stents in the BMS group and 284 stents in the DES group were included. The cumulative medical costs for both matched groups were estimated with the Kaplan-Meier Sample Average (KMSA), and then the incremental cost-effectiveness ratio (ICER) was estimated. PRINCIPAL
FINDINGS: The ICER of DES vs. BMS was NT$ 663,000 per cardiovascular death averted and NT$ 238,394 per cardiovascular death or coronary event averted in five years from the insurer perspective.
CONCLUSION: Percutaneous coronary intervention (PCI) with DES was a more cost-effective strategy than PCI with BMS for CHD patients during the five-year follow-up.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bare-metal stents; Cost-effectiveness analysis; Drug-eluting stents; Health insurance

Mesh:

Year:  2018        PMID: 30578037     DOI: 10.1016/j.healthpol.2018.11.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  3 in total

1.  lncRNA MALAT1/miR-143 axis is a potential biomarker for in-stent restenosis and is involved in the multiplication of vascular smooth muscle cells.

Authors:  Chen Cao; Wei Zhen; Haibin Yu; Li Zhang; Yiling Liu
Journal:  Open Life Sci       Date:  2021-12-20       Impact factor: 0.938

2.  Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis.

Authors:  Z Kevin Lu; Xiaomo Xiong; Taiying Lee; Jun Wu; Jing Yuan; Bin Jiang
Journal:  Front Pharmacol       Date:  2021-10-19       Impact factor: 5.810

3.  Trends in the quality and cost of inpatient surgical procedures in the United States, 2002-2015.

Authors:  Ning Ning; Alex Haynes; John Romley
Journal:  PLoS One       Date:  2021-11-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.